Literature DB >> 15304101

Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling.

Cécile Ged1, Hala Mégarbané, Eliane Chouery, Magalie Lalanne, André Mégarbané, Hubert de Verneuil.   

Abstract

In a Palestinian family, four siblings were shown to express typical and severe congenital erythropoietic porphyria (CEP). A new mutation of the uroporphyrinogen III synthase (UROS) gene was evidenced by systematic sequencing of the UROS gene: the substitution of serine by proline at the amino acid residue 47 (S47P) was present at the homozygous state in the four patients. The mother was heterozygous, the father was not examined. Surprisingly, in one unaffected sister, UROS activity was markedly deficient and UROS gene analysis showed a homozygous mutant profile. The deleterious role of the mutant S47P protein on UROS activity was demonstrated by prokaryotic expression. This observation is the first report of a healthy status associated with homozygosity for a mutation of UROS gene in a severely affected family. We then draw hypotheses to explain the protective phenotype in the homozygous healthy subject.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304101     DOI: 10.1111/j.0022-202X.2004.23401.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  Feline congenital erythropoietic porphyria: two homozygous UROS missense mutations cause the enzyme deficiency and porphyrin accumulation.

Authors:  Sonia Clavero; David F Bishop; Urs Giger; Mark E Haskins; Robert J Desnick
Journal:  Mol Med       Date:  2010-05-12       Impact factor: 6.354

Review 2.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

3.  Mutational analysis of uroporphyrinogen III cosynthase gene in Iranian families with congenital erythropoietic porphyria.

Authors:  Meysam Moghbeli; Mahmood Maleknejad; Azadeh Arabi; Mohammad Reza Abbaszadegan
Journal:  Mol Biol Rep       Date:  2012-02-18       Impact factor: 2.316

Review 4.  Congenital erythropoietic porphyria: Recent advances.

Authors:  Angelika L Erwin; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-12-27       Impact factor: 4.797

5.  Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.

Authors:  Jean-Marc Blouin; Yann Duchartre; Pierre Costet; Magalie Lalanne; Cécile Ged; Ana Lain; Oscar Millet; Hubert de Verneuil; Emmanuel Richard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

6.  A Case of Congenital Erythropoietic Porphyria without Hemolysis.

Authors:  Arun K De; Kallol Das; Archan Sil; Swarnali Joardar
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

7.  The promise of human induced pluripotent stem cells in dental research.

Authors:  Thekkeparambil Chandrabose Srijaya; Padmaja Jayaprasad Pradeep; Rosnah Binti Zain; Sabri Musa; Noor Hayaty Abu Kasim; Vijayendran Govindasamy
Journal:  Stem Cells Int       Date:  2012-05-09       Impact factor: 5.443

8.  The severity of hereditary porphyria is modulated by the porphyrin exporter and Lan antigen ABCB6.

Authors:  Yu Fukuda; Pak Leng Cheong; John Lynch; Cheryl Brighton; Sharon Frase; Vasileios Kargas; Evadnie Rampersaud; Yao Wang; Vijay G Sankaran; Bing Yu; Paul A Ney; Mitchell J Weiss; Peter Vogel; Peter J Bond; Robert C Ford; Ronald J Trent; John D Schuetz
Journal:  Nat Commun       Date:  2016-08-10       Impact factor: 14.919

9.  Congenital Erythropoietic Porphyria with Undescended Testis.

Authors:  Sandeep Arora; Arun Kumar Harith; Neha Sodhi
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.